Publications by authors named "Nanna Luneborg"
Article Synopsis
- The retinal therapeutics field has significantly evolved since the first anti-VEGF therapy was approved in 2004, with a focus on a variety of retinal diseases and improved treatment options, resulting in nearly $10 billion in investments over two decades.
- Treatments have shifted from competing against anti-VEGF therapies to finding ways to reduce patient treatment burden, alongside new initiatives targeting conditions like dry AMD and Retinitis pigmentosa.
- The review highlights successful drug approvals, ongoing challenges, investment dynamics, and future strategies in retinal therapeutics, including innovative approaches like cell-based therapies and gene editing.
During early retinal development, progenitor cells must divide repeatedly to expand the progenitor pool. During G(1) and G(2) of the cell cycle, progenitor cell nuclei migrate back-and-forth across the proliferative zone in a process termed interkinetic nuclear movement. Because division can only occur at the ventricular surface, factors that affect the speed of nuclear movement could modulate the duration of the cell cycle.
View Article and Find Full Text PDFDevelopment of the neural retina is controlled in part by the adjacent retinal pigment epithelium (RPE). To understand better the mechanisms involved, we investigated calcium signalling and gap junctional coupling within and between the RPE and the neural retina in embryonic day (E) 5 chick. We show that the RPE and the ventricular zone (VZ) of the neural retina display spontaneous Ca(2+) transients.
View Article and Find Full Text PDF